International multicenter trials depend on data moving between sites, CROs, sponsors, laboratories, technology providers and central study teams. These parties may operate in several countries and under different privacy frameworks.
This makes cross-border data flow unavoidable. It also makes GDPR compliance an operational and technical challenge, not simply a matter of adding privacy clauses to a contract.
Sponsors and CROs need to understand where clinical data travels, who can access it and which legal safeguards apply at every stage. Their technology must then translate those requirements into practical controls: secure hosting, role-based access, traceable actions and reliable documentation.
The key principle is straightforward: clinical data may move across borders, but the level of protection required by the GDPR must travel with it.
Why multicenter trials raise GDPR complexity
A single multicenter study can involve investigators in the EU, a sponsor outside the EU, a global CRO, central laboratories and technology vendors operating from different regions. Each new party and location adds questions:
- who determines the purposes and means of processing?
- Which organisations act as controllers, joint controllers or processors?
- Where is the data physically hosted?
- From which countries can support teams access it?
- Are any subprocessors located outside the European Economic Area?
- Does remote access from a third country constitute a transfer?
The answers cannot be inferred from job titles alone. Responsibilities depend on the actual decisions made by each organisation. A CRO, for example, may process data on the sponsor’s instructions for some activities while exercising a different level of autonomy for others.
Local differences also matter. Although the GDPR provides a common European framework, Member States may introduce specific rules for processing health and genetic data. Ethics requirements and clinical-trial procedures can vary as well.
This is why GDPR clinical trial planning should begin with a detailed data-flow map. The map should cover collection, transmission, hosting, access, backup, reporting, archiving and deletion, not just the location of the primary database.
The European Data Protection Board’s opinion on the relationship between the Clinical Trials Regulation and the GDPR also makes an important distinction: compliance with clinical trial legislation does not replace the need to identify the appropriate GDPR basis and safeguards for each processing activity.
Legal transfer mechanisms sponsors rely on
Under Chapter V of the GDPR, personal data transferred to a third country or international organization must remain protected under the conditions established by the Regulation. The appropriate mechanism depends on the destination, recipient and circumstances of the transfer.
Adequacy decisions
When the European Commission determines that a country or qualifying framework provides an adequate level of data protection, personal data can generally flow there without an additional Chapter V transfer safeguard.
Sponsors should verify the current status and scope of each decision. An adequacy decision may apply only to particular organisations or processing activities. The Commission maintains the official and updated list of GDPR adequacy decisions.
Standard Contractual Clauses
When no relevant adequacy decision applies, organisations often use the European Commission’s Standard Contractual Clauses for international data transfers.
Signing the SCCs is not necessarily the end of the assessment. The parties should examine whether the laws and practices of the destination country could affect the protections provided by the clauses.
Where necessary, technical, contractual or organisational supplementary measures must be introduced. These may include strong encryption, pseudonymisation, stricter access restrictions or limitations on the data transferred.
Data Processing Agreements
Data Processing Agreements define how a processor handles personal data on behalf of a controller. In a clinical trial, they may govern relationships between the sponsor, CRO, eClinical provider and other vendors. A DPA should cover instructions, confidentiality, security, subprocessor management, incident support, deletion or return of data and audit rights.
However, a DPA is not itself an international transfer mechanism. If the processing involves a restricted transfer, the parties may also need SCCs, an adequacy decision or another safeguard recognised.
Where technology plays a role
Legal documents establish obligations. Technology determines whether those obligations can be applied consistently during daily study operations.
A validated eClinical platform should help sponsors and CROs implement privacy and security requirements through concrete system controls. Relevant capabilities include:
- clearly defined data-hosting locations.
- Encryption in transit and at rest.
- Role-based and least-privilege access.
- Secure authentication.
- Pseudonymisation of participant data.
- Traceable access and modification histories.
- Controlled exports and integrations.
- Backup, retention and recovery procedures.
- Oversight of subprocessors and support access.
Data residency is important, but it should not be treated as the only compliance criterion. An EU-hosted database may still involve an international transfer if personnel or subprocessors located in third country can remotely access personal data.
Similarly, pseudonymised clinical data remains personal data when it can be linked back to a participant using separately held information. Pseudonymisation reduces risk, but it does not automatically remove the processing from the GDPR.
The ACTide eCRF supports structured clinical data collection with standard and customized user profiles, online audit trails, validation controls and secure data-management features. These capabilities can help translate a study’s access model and traceability requirements into controlled workflows.
Technology cannot make a study GDPR-compliant by itself. It can, however, make compliance requirements easier to implement, monitor and demonstrate.
CROs evaluating this operational layer can request an ACTide demo to explore how access, data collection and oversight can be configured for a multicenter study.
Documentation and traceability requirements
Inspection readiness depends on evidence. Sponsors and CROs should be able to reconstruct what data was processed, where it went, why it was transferred and which safeguards were in place. The documentation package may include:
- records of processing activities.
- Study-specific data-flow maps.
- Controller and processor assessments.
- Data Processing Agreements.
- Standard Contractual Clauses, where required.
- Transfer Impact Assessments.
- Data Protection Impact Assessments.
- Lists of subprocessors and hosting locations.
- Technical and organisational measures.
- Access-review records.
- Relevant privacy notices and informed-consent documentation.
- Data-retention and deletion rules.
- Breach-response and escalation procedures.
These records must remain aligned. An updated vendor list has limited value if the study’s data-flow map, contracts and risk assessments still describe the previous architecture.
Documentation should also distinguish informed consent to participate in research from the legal basis used to process personal data. The EDPB warns against treating these as automatically equivalent. The correct analysis depends on the processing purpose and applicable law.
A controlled trial master file helps teams maintain the current and approved versions of essential documents. ACTide eTMF provides centralised documentation, version control, granular profile-based access and a complete audit trail. It can be used as a stand-alone solution or integrated with ACTide eCRF, supporting more consistent oversight across clinical data and trial documentation.
Choosing a technology partner that supports compliance
A technology provider should be evaluated as part of the study’s data-processing chain—not only as a software supplier. Before selecting an eClinical platform, sponsors and CROs should examine:
Hosting and access architecture
Ask where production data, backups and disaster-recovery environments are located. Establish where technical support, system administration and security monitoring are performed.
Security and validation evidence
Review the provider’s security controls, validation approach, audit-trail capabilities, business-continuity measures and relevant certifications. Certifications support due diligence, but they do not replace a study-specific risk assessment.
Subprocessor transparency
The provider should be able to identify relevant subprocessors, their locations and their functions. The contractual process for adding or changing subprocessors should also be clear.
Configurable access and retention
The platform should support granular permissions, access reviews, controlled exports and study-specific retention requirements. A generic security model may not reflect the responsibilities of sponsors, CROs, sites and external reviewers.
Integration governance
Connected systems may create additional data flows. Sponsors should assess what information is exchanged, which party initiates the transfer and whether integrations generate copies in other environments.
The ACTide eClinical Ecosystem brings clinical data collection and study-management capabilities into a modular environment. This can reduce fragmentation and help study teams govern access, documentation and data flows across connected clinical processes.
The objective is not to buy a platform that claims to “solve GDPR.” It is to select a partner whose architecture and documentation allow the sponsor and CRO to meet their own accountability obligations.
A quick GDPR data-transfer checklist
Before starting a multicenter trial, sponsors and CROs should ask four practical questions:
-
Do we have a complete map of every data location and access path?
Include hosting, backups, integrations, support access and subprocessors. -
Does every restricted transfer have an appropriate legal mechanism?
Verify adequacy decisions, SCCs and any required supplementary measures. -
Can our technology enforce the agreed controls?
Confirm permissions, pseudonymisation, audit trails, security and retention capabilities. -
Can we demonstrate our decisions during an inspection?
Keep contracts, assessments, data-flow records and system evidence current and consistent.
GDPR and international data transfer in multicenter trials require legal, operational and technical decisions to work together. Addressing these questions before study startup reduces late-stage remediation and gives teams a stronger foundation for scalable international research.
Request an ACTide demo to discuss how a validated, modular eClinical environment can support controlled data collection, documentation and oversight across your multicenter studies.